immunomodulatory peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-04. Anything still debated is marked as such rather than presented as settled.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
In response to the ruling, MSD initiated counter-litigation in the United States in January 2016 by filing a federal lawsuit which accused its former parent company of "infringing on its trademark" through actions that included the increased usage of "Merck KGaA" and "MERCK" in branding in the US as well as on its social media presence. Further Merck & Co. has also accused the Merck Group of federal trademark dilution, unfair competition, false advertising, deceptive trade practices, breach of contract, and cybersquatting. The case came to a head when a research scientist believed he was communicating with Merck & Co regarding a research grant in oncology, when in fact he was talking with the Merck Group. As a result, Merck & Co. asked the federal court to stop the Merck Group from using "Merck" on any products or marketing materials in the United States. As a direct result, Merck & Co is seeking "all monetary gains, profits, and advantages" made by the Merck Group and three-times the damage, plus additional punitive damages. In April 2020, in the course of litigation of Merck against MSD in Switzerland, the Federal Supreme Court of Switzerland ruled that MSD's use of the "Merck" brand in its global websites could, absent geotargeting mechanisms, have "commercial effect" in Switzerland and could therefore violate Merck's rights (if any) to the "Merck" brand in Switzerland.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a GnRH modulator that activates the GnRH receptor resulting in increased secretion of FSH and LH. Initially it was thought that GnRH agonists could be used as potent and prolonged stimulators of pituitary gonadotropin release, but it was soon recognized that GnRH agonists, after their initial stimulating action – termed a "flare" effect – eventually caused a paradoxical and sustained drop in gonadotropin secretion. This second effect was termed "downregulation" and can be observed after about 10 days. While this phase is reversible upon stopping the medication, it can be maintained when GnRH agonists use is continued for a long time. GnRH agonists can also be administered in a pulsatile manner through the use of a pump to produce a long-term stimulation of gonadotropin secretion, for instance to induce puberty.
=== Gorizia-Tyrol === In 1253 Count Meinhard of Gorizia (Görz) inherited the Tyrolean lands by his marriage to Adelheid, daughter of the last Count Albert IV of Tyrol. When their sons divided their estate in 1271, the elder Meinhard II took Tyrol, for which he was recognized as an immediate lordship. He supported the German king Rudolph of Habsburg against his rival King Ottokar II of Bohemia. In reward, he received the Duchy of Carinthia with the Carniolan march in 1286. In 1307 Meinhard's son Henry was elected King of Bohemia, After his death, he had one surviving daughter, Margaret Maultasch, who could gain the rule only over Tyrol. In 1342 she married Louis V of Wittelsbach, then Margrave of Brandenburg. The red eagle in Tyrol's coat of arms may derive from the Brandenburg eagle at the time when she and her husband ruled Tyrol and Brandenburg in personal union, though the Tyrolean eagle had already appeared in the 13th century. Louis V died in 1361, followed by Margaret's son Meinhard III two years later. Lacking any descendants to succeed her, she bequeathed the county to Rudolph IV of Habsburg, Duke of Austria in 1363. He was recognized by the House of Wittelsbach in 1369. From that time onward, Tyrol was ruled by various lines of the Austrian House of Habsburg, who held the title of count.
Other than for vision, the metabolic functions of vitamin A are mediated by all-trans-retinoic acid (RA). The formation of RA from retinal is irreversible. To prevent accumulation of RA it is oxidized and eliminated fairly quickly, i.e., has a short half-life. Three cytochromes catalyze the oxidation of retinoic acid. The genes for Cyp26A1, Cyp26B1 and Cyp26C1 are induced by high levels of RA, providing a self-regulating feedback loop.
== Nazi Germany (1933–1945) == Soon after Adolf Hitler was appointed as chancellor in 1933, the German Reichstag (parliament) passed the Enabling Act (German: Ermächtigungsgesetz), officially titled "Law for Removing the Distress of People and Reich" (German: Gesetz zur Behebung der Not von Volk und Reich), which effectively gave the chancellor the power of a dictator. This event marked the end of the Weimar Republic and the beginning of Nazi Germany. Hitler thereupon destroyed all democratic systems and consolidated all power to himself. After the death of president Paul von Hindenburg in 1934, Hitler merged the offices of chancellor and president in his own person and called himself Führer und Reichskanzler. Political parties: NSDAP
Sources: en.wikipedia.org
== Regulation == Among the lipid-binding actin regulatory proteins, gelsolin (like cofilin) preferentially binds polyphosphoinositide (PPI). The binding sequences in gelsolin closely resemble the motifs in the other PPI-binding proteins. Gelsolin's activity is stimulated by calcium ions (Ca2+). Although the protein retains its overall structural integrity in both activated and deactivated states, the S6 helical tail moves like a latch depending on the concentration of calcium ions. The C-terminal end detects the calcium concentration within the cell. When there is no Ca2+ present, the tail of S6 shields the actin-binding sites on one of S2's helices. When a calcium ion attaches to the S6 tail, however, it straightens, exposing the S2 actin-binding sites. The N-terminal is directly involved in the severing of actin. S2 and S3 bind to the actin before the binding of S1 severs actin-actin bonds and caps the barbed end. Gelsolin can be inhibited by a local rise in the concentration of phosphatidylinositol (4,5)-bisphosphate (PIP2), a PPI. This is a two step process. Firstly, (PIP2) binds to S2 and S3, inhibiting gelsolin from actin side binding. Then, (PIP2) binds to gelsolin's S1, preventing gelsolin from severing actin, although (PIP2) does not bind directly to gelsolin's actin-binding site. Gelsolin's severing of actin, in contrast to the severing of microtubules by katanin, does not require any extra energy input.
=== Available forms === Finasteride (brand names Proscar, Propecia) inhibits the function of two of the isoenzymes (types 2 and 3) of 5α-reductase. It decreases circulating DHT levels by up to about 70%. Dutasteride (brand name Avodart) inhibits all three 5α-reductase isoenzymes and can decrease DHT levels by 95%. It can also reduce DHT levels in the prostate by 97 to 99% in men with prostate cancer. Epristeride (brand names Aipuliete, Chuanliu) is marketed in China for the treatment of benign prostatic hyperplasia. However, it can only decrease circulating DHT levels by about 25 to 54%. Alfatradiol (brand names Ell-Cranell Alpha, Pantostin) is a topical 5-ARI used to treat pattern hair loss in Europe.
=== Patentability issues === As indicated above, some mammals typically used for food production (such as goats, sheep, pigs, and cows) have been modified to produce non-food products, a practice sometimes called pharming. Use of genetically modified goats has been approved by the FDA and EMA to produce ATryn, i.e. recombinant antithrombin, an anticoagulant protein drug. These products "produced by turning animals into drug-manufacturing 'machines' by genetically modifying them" are sometimes termed biopharmaceuticals. The patentability of such biopharmaceuticals and their process of manufacture is uncertain. Probably, the biopharmaceuticals themselves so made are unpatentable, assuming that they are chemically identical to the preexisting drugs that they imitate. Several 19th-century United States Supreme Court decisions hold that a previously known natural product manufactured by artificial means cannot be patented. An argument can be made for the patentability of the process for manufacturing a biopharmaceutical, however, because genetically modifying animals so that they will produce the drug is dissimilar to previous methods of manufacture; moreover, one Supreme Court decision seems to hold open that possibility. On the other hand, it has been suggested that the recent Supreme Court decision in Mayo v.
Furthermore, it is possible to transplant freeze-dried donor tissue. The freeze-drying process ensures this tissue is dead, so there is no chance of rejection. Research from two trials in Iran provide low to moderate evidence that graft rejection is more likely to occur in penetrating keratoplasty than in DALK, though the likelihood for graft failure were similar with both procedures.
Sources: en.wikipedia.org
== External links == Eosinophil+Major+Basic+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P13727 (Bone marrow proteoglycan) at the PDBe-KB.
=== Dinoflagellates in the Adriatic Sea === The marine dinoflagellates: Prorocentrum micans, Lingulodinium polyedra, Gymnodinium sp., and Alexandrium tamarense, were collected from the Adriatic Sea during red-tide blooms and their 4-methyl sterol content was investigated. Dinosterol is the major component in P. micans, L. polyedra, and Gymnodinium strains, suggesting that dinosterol is a good biomarker because of its high abundance in most of the analyzed dinoflagellates.
== D == D-arabinitol 2-dehydrogenase - D-arabinose 1-dehydrogenase (NAD(P)+) - database search - degeneracy (biology) - deletion - denaturation - denaturing gel - deoxyribonuclease (DNase) - deoxyribonucleic acid - deoxyribonucleotide - deoxyuridine phosphorylase - diabetes mellitus - dideoxy sequencing - dideoxyribonucleotide - diethyl 2-methyl-3-oxosuccinate reductase - dihydrochelirubine 12-monooxygenase - dimethyl sulfide:cytochrome c2 reductase - diploid - direct repeat - directionality - DLG2-AS1 - DNA ligase -DNA Bank - DNA polymerase - DNA replication - DNA sequencing - DNase - dominant - dot blot - double helix - downstream (DNA) - downstream (transduction) - drimenol cyclase- ds - duplex -
Many women were coerced into have the tubal ligation procedure done right after postpartum which was paid for using federal money that was dispersed into the War On Poverty first initiated by Lyndon B. Johnson. Many of these sterilizations were done involuntarily and without consent. Oftentimes, these women signed off on paperwork without being able to read the English language. This sterilization was seen as a result of barriers experienced by Spanish speaking women. Other times, they were told it was necessary in order to maintain their welfare benefits. It became common to sterilize women after giving birth whether by tubal ligation or hysterectomy. Even when the women did consent, it was often under false pretenses that the procedure could be reversed if they decided to have children again in the future.
=== Targets === Aptamer targets can include small molecules and heavy metal ions, larger ligands such as proteins, and even whole cells. These targets include lysozyme, thrombin, human immunodeficiency virus trans-acting responsive element (HIV TAR), hemin, interferon γ, vascular endothelial growth factor (VEGF), prostate specific antigen (PSA), dopamine, and the non-classical oncogene, heat shock factor 1 (HSF1). Aptamers have been generated against cancer cells, prions, bacteria, and viruses. Viral targets of aptamers include influenza A and B viruses, Respiratory syncytial virus (RSV), SARS coronavirus (SARS-CoV) and SARS-CoV-2. Aptamers may be particularly useful for environmental science proteomics. Antibodies, like other proteins, are more difficult to sequence than nucleic acids. They are also costly to maintain and produce, and are at constant risk of contamination, as they are produced via cell culture or are harvested from animal serum. For this reason, researchers interested in little-studied proteins and species may find that companies will not produce, maintain, or adequately validate the quality of antibodies against their target of interest. By contrast, aptamers are simple to sequence and cost nothing to maintain, as their exact structure can be stored digitally and synthesized on demand. This may make them more economically feasible as research tools for underfunded biological research subjects. Aptamers exist for plant compounds, such as theophylline (found in tea) and abscisic acid (a plant immune hormone).
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.